Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice-Reference-Cited by-同舟云学术

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice

Published:2017-01-23 Issue:4 Volume:241 Page:511-521
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

van de Ven Marieke¹²,van der Burg Eline¹,van der Gulden Hanneke¹,Klarenbeek Sjoerd¹,Bouwman Peter¹,Jonkers Jos¹

Affiliation:

1. Division of Molecular Pathology and Cancer Genomics Netherlands; The Netherlands Cancer Institute; Amsterdam The Netherlands

2. MCCA Preclinical Intervention Unit; The Netherlands Cancer Institute; Amsterdam The Netherlands

Funder

Seventh Framework Programme

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference49 articles.

1. How many more breast cancer predisposition genes are there?;Easton;Breast Cancer Res BCR,1999

2. Hereditary breast cancer: new genetic developments, new therapeutic avenues;Campeau;Hum Genet,2008

3. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE;Mavaddat;J Natl Cancer Inst,2013

4. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer;Whittemore;Am J Hum Genet,1997

5. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada;Risch;J Natl Cancer Inst,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice;Scientific Reports;2021-01-13

2. Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2020-04

3. BRCA1 -associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling;The Journal of Pathology;2018-07-04